Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jeffrey Kroll Adams is active.

Publication


Featured researches published by Jeffrey Kroll Adams.


Cancer Research | 2009

Targeting Sphingosine Kinase 1 Inhibits Akt Signaling, Induces Apoptosis, and Suppresses Growth of Human Glioblastoma Cells and Xenografts

Dmitri Kapitonov; Jeremy C. Allegood; Clint Mitchell; Nitai C. Hait; Jorge A. Almenara; Jeffrey Kroll Adams; Robert Elliot Zipkin; Paul Dent; Tomasz Kordula; Sheldon Milstien; Sarah Spiegel

Sphingosine-1-phosphate is a potent sphingolipid mediator of diverse processes important for brain tumors, including cell growth, survival, migration, invasion, and angiogenesis. Sphingosine kinase 1 (SphK1), one of the two isoenzymes that produce sphingosine-1-phosphate, is up-regulated in glioblastoma and has been linked to poor prognosis in patients with glioblastoma multiforme (GBM). In the present study, we found that a potent isotype-specific SphK1 inhibitor, SK1-I, suppressed growth of LN229 and U373 glioblastoma cell lines and nonestablished human GBM6 cells. SK1-I also enhanced GBM cell death and inhibited their migration and invasion. SK1-I rapidly reduced phosphorylation of Akt but had no significant effect on activation of extracellular signal-regulated kinase 1/2, another important survival pathway for GBM. Inhibition of the concomitant activation of the c-Jun-NH(2)-kinase pathway induced by SK1-I attenuated death of GBM cells. Importantly, SK1-I markedly reduced the tumor growth rate of glioblastoma xenografts, inducing apoptosis and reducing tumor vascularization, and enhanced the survival of mice harboring LN229 intracranial tumors. Our results support the notion that SphK1 may be an important factor in GBM and suggest that an isozyme-specific inhibitor of SphK1 deserves consideration as a new therapeutic agent for this disease.


European Journal of Pharmacology | 2002

Ceramide 1-(2-cyanoethyl) phosphate enhances store-operated Ca2+ entry in thyroid FRTL-5 cells.

Kid Törnquist; Cia Ramström; Britt Rudnäs; Karel D. Klika; Benoit Dugué; Jeffrey Kroll Adams; Robert Elliot Zipkin; Kalevi Pihlaja; Michael Pasternack

Sphingolipid derivatives cause diverse effects towards the regulation of intracellular free Ca(2+) concentrations ([Ca(2+)](i)) in a multitude of nonexcitable cells. In the present investigation, the effect of C-8 ceramide-1-(2-cyanoethyl) phosphate (C1CP) on store-operated Ca(2+) (SOC) entry was investigated. C1CP evoked a modest increase in [Ca(2+)](i). The increase was inhibited by the SOC channel antagonist 1-(beta-[3-(4methoxyphenyl)propoxy]-4-methoxyphenethyl)-1H-imidazole (SKF96365) but not by overnight pretreatment of the cells with pertussis toxin. C1CP did not invoke the production of inositol phosphates. When cells were stimulated with both C1CP and thapsigargin, the thapsigargin-invoked increase in [Ca(2+)](i) was enhanced in comparison to control cells. When Ca(2+) was added to cells treated with both C1CP and thapsigargin in a Ca(2+)-free buffer, the increase in [Ca(2+)](i) was enhanced in comparison to control cells. In patch-clamp experiments, C1CP hyperpolarized the membrane potential (E(m)) of the cells and attenuated the thapsigargin-invoked depolarization of the E(m). The effects of C1CP came, in part, as a result of a decreased conductance of the cell membrane towards Cl(-) ions, as C1CP in a Cl(-)-free solution also enhanced Ca(2+) entry. Barium 2-cyanoethylphosphate (Ba2Cy), which also contains the 2-cyanoethyl group, did not modulate thapsigargin-invoked changes in [Ca(2+)](i) nor did it modulate the E(m). In conclusion, C1CP enhances SOC entry, in part, via hyperpolarization of the E(m) and attenuation of the thapsigargin-invoked membrane depolarization, thus increasing the electrochemical gradient for Ca(2+) ions. Hence, C1CP may be a useful reagent for investigating the cellular effects of ceramide derivatives.


Blood | 2008

A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia

Steven W. Paugh; Barbara S. Paugh; Mohamed Rahmani; Dmitri Kapitonov; Jorge A. Almenara; Tomasz Kordula; Sheldon Milstien; Jeffrey Kroll Adams; Robert Elliot Zipkin; Steven Grant; Sarah Spiegel


Bioorganic & Medicinal Chemistry | 2007

Potential anti-inflammatory actions of the elmiric (lipoamino) acids

Sumner Burstein; Jeffrey Kroll Adams; Heather B. Bradshaw; Cristian Fraioli; Ronald G. Rossetti; Rebecca Salmonsen; John W. Shaw; J. Michael Walker; Robert Elliot Zipkin; Robert B. Zurier


Archive | 2009

Sphingosine kinase type 1 inhibitors, compositions and processes for using same

Robert Elliot Zipkin; Sarah Spiegel; Jeffrey Kroll Adams


Archive | 2009

Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same

Sarah Spiegel; Robert Elliot Zipkin; Jeffrey Kroll Adams


Archive | 2009

SPHINGOSINE KINASE TYPE 1 INHIBITORS, AND PROCESSES FOR USING SAME

Sarah Spiegel; Robert Elliot Zipkin; Jeffrey Kroll Adams


Archive | 2012

SPHINGOSINE KINASE TYPE 1 INHIBITORS

Sarah Spiegel; Robert Elliot Zipkin; Jeffrey Kroll Adams


Archive | 2017

PRODUCTION OF PHARMACEUTICAL COMPOSITIONS

Robert Elliot Zipkin; Jeffrey Kroll Adams; Sarah Spiegel


Archive | 2016

Sphingosine Kinase Type 1 Inhibitors and Uses Thereof

Sarah Spiegel; Robert Elliot Zipkin; Jeffrey Kroll Adams

Collaboration


Dive into the Jeffrey Kroll Adams's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sarah Spiegel

Virginia Commonwealth University

View shared research outputs
Top Co-Authors

Avatar

Dmitri Kapitonov

Virginia Commonwealth University

View shared research outputs
Top Co-Authors

Avatar

Jorge A. Almenara

Virginia Commonwealth University

View shared research outputs
Top Co-Authors

Avatar

Sheldon Milstien

Virginia Commonwealth University

View shared research outputs
Top Co-Authors

Avatar

Barbara S. Paugh

Virginia Commonwealth University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Steven W. Paugh

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Clint Mitchell

Virginia Commonwealth University

View shared research outputs
Researchain Logo
Decentralizing Knowledge